Telotristat ethyl Withdrawn Phase 3 Trials for Small Intestinal NET / Carcinoid Heart Disease Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04065165Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome